Ari Bio will participate in BioEurope in 2025 next month...There's a lot of interest in Alzheimer's drugs
Oct 27, 2025
Aribio (CEO Jeong Jae-joon) announced that it will participate in the world's largest bio-partnering conference 'Bio-Europe 2025' to be held in Vienna, Austria from November 3-5.
BIO-Europe 2025 is a global representative networking event where pharmaceutical companies, bio-innovation companies, and investors from all over the world gather to actively transfer new drug technology and attract investment.
Aribio has confirmed more than 50 partnering meetings with global pharmaceutical and institutional investors, with the participation of Fred Kim, U.S. branch manager, and Dr. Tanya Xi, MD, PhD, MBA, business development director.
At this meeting, ▲ additional exclusive rights negotiations for the Alzheimer's disease treatment 'AR1001', which is undergoing phase 3 clinical trials worldwide, ▲ Cognitive function improvement brain stimulation medical device 'Herzion' development cooperation ▲ Joint development of new pipelines and attracting investment will be discussed.
"Global pharmaceutical companies are very interested in the Alzheimer's treatment and related pipelines currently being developed by Ari Bio. The meeting will focus on exclusive sales rights of AR1001 in North America and Europe, especially in the final phase of phase 3 clinical trials," said Fred Kim, head of Ari Bio's U.S. branch.
"BIO-Europe is an important opportunity to specifically connect global partnerships," Dr. Tanya Shi said. "We will actively seek collaboration in various areas, including Aribio's next-generation new drug pipeline and medical device development program."
Aribio is leading the development of neurodegenerative disease treatments and is expanding its strategic collaboration this year through major global partnering events such as BIO-Europe, BIO-USA, and JP Morgan Healthcare Conference (JPM).
Meanwhile, Aribio is pursuing a merger with KOSDAQ-listed Sorux, and the scheduled date is January 20, 2026.
BIO-Europe 2025 is a global representative networking event where pharmaceutical companies, bio-innovation companies, and investors from all over the world gather to actively transfer new drug technology and attract investment.
Aribio has confirmed more than 50 partnering meetings with global pharmaceutical and institutional investors, with the participation of Fred Kim, U.S. branch manager, and Dr. Tanya Xi, MD, PhD, MBA, business development director.
At this meeting, ▲ additional exclusive rights negotiations for the Alzheimer's disease treatment 'AR1001', which is undergoing phase 3 clinical trials worldwide, ▲ Cognitive function improvement brain stimulation medical device 'Herzion' development cooperation ▲ Joint development of new pipelines and attracting investment will be discussed.
"Global pharmaceutical companies are very interested in the Alzheimer's treatment and related pipelines currently being developed by Ari Bio. The meeting will focus on exclusive sales rights of AR1001 in North America and Europe, especially in the final phase of phase 3 clinical trials," said Fred Kim, head of Ari Bio's U.S. branch.
"BIO-Europe is an important opportunity to specifically connect global partnerships," Dr. Tanya Shi said. "We will actively seek collaboration in various areas, including Aribio's next-generation new drug pipeline and medical device development program."
Aribio is leading the development of neurodegenerative disease treatments and is expanding its strategic collaboration this year through major global partnering events such as BIO-Europe, BIO-USA, and JP Morgan Healthcare Conference (JPM).
Meanwhile, Aribio is pursuing a merger with KOSDAQ-listed Sorux, and the scheduled date is January 20, 2026.
|
This article was translated by Naver AI translator.
